• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文OA文献 >Prognostic significance of MGMT promoter methylation in diffuse glioma patients
【2h】

Prognostic significance of MGMT promoter methylation in diffuse glioma patients

机译：MgMT启动子甲基化在弥漫性胶质瘤患者中的预后意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Current treatment options for diffuse glioma patients include maximum safe resection followed by a combination of radiation therapy and chemotherapy with alkylating agents. The DNA-repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) counteracts the cytotoxic effect of alkylating agents and mediates chemoresistance. Disruption of the DNA methylation mechanism in diffuse glioma cells results in epigenetic silencing of MGMT through methylation of cytidine-phosphate-guanosine dinucleotides (CpG) in the promoter region. The methylation status of MGMT is widely accepted to be a strong prognostic factor in diffuse glioma patients. This study was designed to screen Serbian diffuse glioma patients for hypermethylation of the MGMT promoter and to estimate its impact on overall survival. The results obtained in our study on 33 samples of diffuse glioma detected a positive methylation status in 17 patients (51.5%) by methylation-specific polymerase chain reaction. The positive methylation status of the MGMT promoter did not correlate with overall survival. In this study group, the patients older than 50 years had significantly lower overall survival in comparison with younger patients (7 months–19 months median survival). Extent of tumour resection also had influence on overall survival of patients. The relevance of the MGMT promoter methylation status should be further evaluated in a larger study and in association with other markers.
机译：弥漫性胶质瘤患者的当前治疗方案包括最大安全切除，然后用烷基化剂结合放射治疗和化疗。 DNA修复酶O6-甲基胍-DNA甲基转移酶（MGMT）抵消了烷基化试剂的细胞毒性作用并介导化学化。弥漫性胶质瘤细胞中DNA甲基化机制的破坏导致MGMT通过启动子区中胞嘧啶 - 磷酸胍氨核苷酸二核苷酸（CPG）的甲基化沉默。众所周知，MgMT的甲基化状态是弥漫性胶质瘤患者的强预后因素。本研究旨在筛选塞尔维亚弥漫性胶质瘤患者，用于MGMT启动子的高甲基化，并估计其对整体存活的影响。在我们对33例弥漫性胶质瘤样品中获得的结果检测了通过甲基化特异性聚合酶链反应检测17名患者（51.5％）的正甲基化状态。 MgMT启动子的正甲基化状态与总存活率无关。在这项研究组中，与年龄较小的患者（7个月 - 19个月的生存率）相比，50岁的患者显着降低了整体生存率。肿瘤切除程度也对患者的整体存活率产生影响。应在更大的研究中进一步评估MGMT启动子甲基化状态的相关性并与其他标记相关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号